Elke Kalbe1, Sarah Petra Rehberg1, Ines Heber2, Martin Kronenbuerger2, Jörg B Schulz3, Alexander Storch4, Katharina Linse5, Christine Schneider5, Susanne Gräber6, Inga Liepelt-Scarfone6, Daniela Berg7, Judith Dams8, Monika Balzer-Geldsetzer8, Rüdiger Hilker9, Carola Oberschmidt9, Karsten Witt10, Nele Schmidt10, Brit Mollenhauer11, Claudia Trenkwalder11, Annika Spottke12, Sandra Roeske12, Hans-Ulrich Wittchen13, Oliver Riedel14, Richard Dodel8. 1. Medical Psychology, Neuropsychology and Gender Studies, Center for Neuropsychological Diagnostics and Intervention (CeNDI), University Hospital Cologne, Cologne, Germany. 2. Department of Neurology, University Hospital, RWTH University Aachen, Aachen, Germany. 3. Department of Neurology, University Hospital, RWTH University Aachen, Aachen, Germany JARA Brain Institute 2, RWTH University and Forschungszentrum Jülich, Germany. 4. Division of Neurodegenerative Diseases, Department of Neurology, Technische Universität Dresden, Dresden, Germany Department of Neurology, University of Rostock, Rostock, Germany. 5. Division of Neurodegenerative Diseases, Department of Neurology, Technische Universität Dresden, Dresden, Germany. 6. German Center of Neurodegenerative Diseases and Hertie Institute for Clinical Brain Research, Tübingen, Germany. 7. German Center of Neurodegenerative Diseases and Hertie Institute for Clinical Brain Research, Tübingen, Germany Department of Neurology, Christian Albrecht University, Kiel, Germany. 8. Department of Neurology, Philipps University Marburg, Marburg, Germany. 9. Department of Neurology, J.W. Goethe University, Frankfurt/Main, Germany. 10. Department of Neurology, Christian Albrecht University, Kiel, Germany. 11. Paracelsus-Elena Clinic, Centre of Parkinsonism and Movement Disorders, Kassel, Germany. 12. Department of Neurology, University Hospital Bonn, and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany. 13. Institute of Clinical Psychology and Psychotherapy, Technische Universität Dresden, Dresden, Germany. 14. Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology, Bremen, Germany.
Abstract
OBJECTIVE: Inconsistent results exist regarding the cognitive profile in patients with Parkinson's disease with mild cognitive impairment (PD-MCI). We aimed at providing data on this topic from a large cohort of patients with PD-MCI. METHODS: Sociodemographic, clinical and neuropsychological baseline data from patients with PD-MCI recruited in the multicentre, prospective, observational DEMPARK/LANDSCAPE study were analysed. RESULTS: 269 patients with PD-MCI (age 67.8±7.4, Unified Parkinson's Disease Rating Scale (UPDRS-III) scores 23.2±11.6) were included. PD-MCI subtypes were 39.4% non-amnestic single domain, 30.5% amnestic multiple domain, 23.4% non-amnestic multiple domain and 6.7% amnestic single domain. Executive functions were most frequently impaired. The most sensitive tests to detect cognitive dysfunctions were the Modified Card Sorting Test, digit span backwards and word list learning direct recall. Multiple stepwise regression analyses showed that global cognition, gender and age, but not education or disease-related parameters predicted PD-MCI subtypes. CONCLUSIONS: This study with the so far largest number of prospectively recruited patients with PD-MCI indicates that non-amnestic PD-MCI is more frequent than amnestic PD-MCI; executive dysfunctions are the most typical cognitive symptom in PD-MCI; and age, gender and global cognition predict the PD-MCI subtype. Longitudinal data are needed to test the hypothesis that patients with PD-MCI with specific cognitive profiles have different risks to develop dementia. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVE: Inconsistent results exist regarding the cognitive profile in patients with Parkinson's disease with mild cognitive impairment (PD-MCI). We aimed at providing data on this topic from a large cohort of patients with PD-MCI. METHODS: Sociodemographic, clinical and neuropsychological baseline data from patients with PD-MCI recruited in the multicentre, prospective, observational DEMPARK/LANDSCAPE study were analysed. RESULTS: 269 patients with PD-MCI (age 67.8±7.4, Unified Parkinson's Disease Rating Scale (UPDRS-III) scores 23.2±11.6) were included. PD-MCI subtypes were 39.4% non-amnestic single domain, 30.5% amnestic multiple domain, 23.4% non-amnestic multiple domain and 6.7% amnestic single domain. Executive functions were most frequently impaired. The most sensitive tests to detect cognitive dysfunctions were the Modified Card Sorting Test, digit span backwards and word list learning direct recall. Multiple stepwise regression analyses showed that global cognition, gender and age, but not education or disease-related parameters predicted PD-MCI subtypes. CONCLUSIONS: This study with the so far largest number of prospectively recruited patients with PD-MCI indicates that non-amnestic PD-MCI is more frequent than amnestic PD-MCI; executive dysfunctions are the most typical cognitive symptom in PD-MCI; and age, gender and global cognition predict the PD-MCI subtype. Longitudinal data are needed to test the hypothesis that patients with PD-MCI with specific cognitive profiles have different risks to develop dementia. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Sirwan K L Darweesh; Frank J Wolters; Ronald B Postuma; Bruno H Stricker; Albert Hofman; Peter J Koudstaal; M Kamran Ikram; M Arfan Ikram Journal: JAMA Neurol Date: 2017-12-01 Impact factor: 18.302
Authors: Martin Gorges; Martin S Kunz; Hans-Peter Müller; Inga Liepelt-Scarfone; Alexander Storch; Richard Dodel; Rüdiger Hilker-Roggendorf; Daniela Berg; Elke Kalbe; Heiko Braak; Kelly Del Tredici; Simon Baudrexel; Hans-Jürgen Huppertz; Jan Kassubek Journal: Hum Brain Mapp Date: 2019-12-02 Impact factor: 5.038